Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only. Prescribing Information and adverse event reporting information can be found below.

      botox

      +30 years of global experience across multiple conditions1-4

      UROLOGY*

      Having overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) can impact your patient's quality of life when left untreated.5 Learn about the impact on patients and how BOTOX® can alleviate symptoms of OAB and NDO6

      OVERACTIVE BLADDER (OAB)
      NEUROGENIC DETRUSOR OVERACTIVITY (NDO)
      botox

      +30 years of global experience across multiple conditions1-4

      UROLOGY*

      Having overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) can impact your patient's quality of life when left untreated.5 Learn about the impact on patients and how BOTOX® can alleviate symptoms of OAB and NDO6

      OVERACTIVE BLADDER (OAB)
      NEUROGENIC DETRUSOR OVERACTIVITY (NDO)

       

      BOTOX® has an efficacy and tolerability profile from
      +30 years of global use in a range of conditions2-4

      Explore the licensed indications timeline1

      First approved by the US FDA in 19897 and 25 years of experience in the UK1

      Timeline icon displaying the year 1994

      UK approval:

      blepharospasm and hemifacial spasm1

      Timeline icon displaying the year 1997

      UK approval:

      idiopathic cervical dystonia1

      Timeline icon displaying the year 1998

      UK approval:

      juvenile cerebral palsy1

      Timeline icon displaying the year 2004

      UK approval:

      axillary hyperhidrosis1

      Timeline icon displaying the year 2002

      UK approval:

      post-stroke wrist and hand spasticity1

      Timeline icon displaying the year 2010

      UK approval:

      chronic migraine1

      Timeline icon displaying the year 2012

      UK approval:

      neurogenic detrusor overactivity1

      Timeline icon displaying the year 2013

      UK approval:

      overactive bladder1

      Year pic09

      UK approval:

      post-stroke ankle spasticity1

      Timeline icon displaying the year 2019

      UK approval:

      post-stroke ankle and foot spasticity1

      Timeline icon displaying the year 2021

      UK approval:

      ankle and foot spasticity in paediatric cerebral palsy1

      Timeline icon displaying the year 2022

      UK approval:

      elbow, wrist and hand in paediatric cerebral palsy1

      Timeline icon displaying the year 2023

      UK approval:

      upper and lower limb spasticity1

      Previous
      Next

      *BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.6

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. Stewart W F, Van Rooyen J B et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336
      6. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk
      7. Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-939

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. Stewart W F, Van Rooyen J B et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336
      6. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk
      7. Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel). 2012;4(10):913-939

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: January 2026. UK-BTX-250141.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250400. Date of preparation December 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.